Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592391 | 1.00 | AHR (0.42) | AHRTP53TSHRHSD17B10CYP3A4 | |
| SCHEMBL28721072 | 0.85 | AHR (0.42) | AHRTP53TSHRHSD17B10CYP3A4 | |
| SCHEMBL11379395 | 0.78 | AHR (0.36) | AHRTP53TSHRHSD17B10CYP3A4 | |
| SCHEMBL12474020 | 0.76 | AHR (0.34) | AHRTP53TSHRHSD17B10CYP3A4 | |
| SCHEMBL7860089 | 0.70 | LMNA (0.47) | AHRTSHRHSD17B10CYP3A4IDO1 | |
| SCHEMBL7858638 | 0.68 | ALDH1A1 (0.41) | TP53TSHRIDO1ALDH1A1NOTUM | |
| SCHEMBL13698270 | 0.63 | CYP2D6 (0.42) | ALDH1A1GAAMAPTALOX12 | |
| SCHEMBL14983491 | 0.62 | ALDH1A1 (0.43) | TSHRHSD17B10CYP3A4CYP1B1ALDH1A1 | |
| SCHEMBL29490721 | 0.61 | — | — | |
| SCHEMBL529658 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9884875-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-20150353578-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-10 | — | — | US | disclosed |
| US-9150591-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150073137-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-12 | — | — | US | disclosed |
| US-8916551-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8778934-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140080817-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8575154-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080817-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | AHR 3519/4885TP53 34/4885TSHR 3295/4885 |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20150073137-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20150353578-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | AHR 342/4885TP53 2902/4885TSHR 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.